Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis

Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis

Abstract Introduction This article aims to describe malignancies in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), or non-radiographic axial spondyloarthritis (nr-axSpA) treated with upadacitinib (UPA) or active comparators. Methods This integrated s...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Andrea Rubbert-Roth, Adriana M. Kakehasi, Tsutomu Takeuchi, Marc Schmalzing, Hannah Palac, Derek Coombs, Jianzhong Liu, Samuel I. Anyanwu, Ralph Lippe, Jeffrey R. Curtis
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: Adis, Springer Healthcare 2023-11-01
Sarja:Rheumatology and Therapy
Aiheet:
Ankylosing spondylitis (AS)
Janus kinase (JAK) inhibitor
Malignancy
Nonmelanoma skin cancer (NMSC)
Non-radiographic axial spondyloarthritis (nr-axSpA)
Psoriatic arthritis (PsA)
Linkit:https://doi.org/10.1007/s40744-023-00621-6

Internet

https://doi.org/10.1007/s40744-023-00621-6

Samankaltaisia teoksia